On June 8, GenScript Biotech fell 7.04% in regular trading, trading at 12.02 HKD/share, with trading volume of approximately 156 million HKD.

The decline was driven by a broad sell-off across the pharmaceutical outsourcing (CXO) sector. WuXi Biologics dropped over 7%, Frontage Holdings fell more than 7%, and WuXi XDC declined over 6%, with sector-wide linkage effects significantly intensifying downward pressure on individual stocks. Simultaneously, the broader Hong Kong market weakened notably, with the Hang Seng Tech Index falling 2.4%, reflecting a marked retreat in overall market risk appetite.

From an industry perspective, analysts note that while global biopharmaceutical financing has shown signs of improvement in early stages, structural divergence persists across CXO sub-sectors. Funding pressures on early-stage biotech startups remain unresolved, contributing to cautious sentiment toward the sector despite expectations of gradual recovery in innovative drug R&D demand throughout the year.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)